Bluejay Diagnostics (BJDX) Long-Term Deferred Tax (2020 - 2022)

Bluejay Diagnostics has disclosed Long-Term Deferred Tax across 3 years of filings, most recently posting $2.7 million for Q4 2022.

• Long-Term Deferred Tax for Q4 2022 came in at $2.7 million, up 200.0% year-over-year; the trailing twelve-month figure through Dec 2022 was $2.7 million (up 200.0% YoY), and the FY2022 annual result was $2.7 million, up 200.0% from the prior year.
• Long-Term Deferred Tax came in at $2.7 million for Q4 2022 at Bluejay Diagnostics, up from $900000.0 in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $2.7 million in Q4 2022 to a low of $900000.0 in Q4 2021.
• The 3-year median for Long-Term Deferred Tax is $1.1 million (2020), against an average of $1.6 million.
• Across the five-year window, Long-Term Deferred Tax decreased 15.9% in 2021 and surged 200.0% in 2022, its largest moves.
• Bluejay Diagnostics' Long-Term Deferred Tax stood at $1.1 million in 2020, then declined by 15.9% to $900000.0 in 2021, then soared by 200.0% to $2.7 million in 2022.
• The last three Long-Term Deferred Tax figures came in at $2.7 million (Q4 2022), $900000.0 (Q4 2021), and $1.1 million (Q4 2020), per Business Quant data.